Dare Bioscience, Inc.

Welcome to the conference call hosted by DARE Bioscience to review the company's second quarter financial results and to provide a general business update. This call has been recorded. My name is Leonardo, and I will be your operator today. With us today from DARE are Sabina Martusi-Johnson, President and Chief Executive Officer, and Marty Herring-Layton, Chief Accounting Officer. Ms. Herring-Layton, please proceed.

Good afternoon and welcome to the DARE Bioscience Financial Results and Business Update call for the quarter ended June 30th, 2024. Today we will review our second quarter results and discuss developments and expectations for our pipeline and portfolio. I'd like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings including on form 10Q for the quarter ended June 30th, 2024, which was filed today. I would also like to point out that the content of this call includes time sensitive information that is current as of today, August 12th, 2024. SARA undertakes no obligation to update any forward looking statements to reflect new information or developments after this call, except as required by law. I will now turn it over to Sabrina.

Thank you. I always like to start our quarterly calls by taking a minute to remind those of you who may be newer to the DARE story of our purpose and our mission. We believe DARE is the only publicly traded company focused solely on women's health, pharmaceutical product development broadly, and we remain dedicated to advancing disruptive products for the health and well-being of women through clinical development, regulatory review, and ultimately to market. Our commitment and focus is to improve health outcomes and the lives of women by leveraging the basic science and pharmacology that is understood about certain active pharmaceutical ingredients and marketed products to accelerate innovative treatments that women want and need by boldly addressing existing therapeutic gaps. We seek to optimize these treatments for our target indications to enhance outcomes, convenience, and side effect profile, or to address a novel indication where the pharmacology is well-suited but has not previously been applied to the indication in question for women. We believe we have the broadest portfolio of potential high-impact, first-in-category product candidates to improve the health and well-being of women, many of which have already demonstrated proof of concept, and that our robust pipeline positions us well for the short, medium, and long term. During our last update call, we discussed the strides we made last year to advance innovative therapies for women and the key milestones anticipated for 2024. In addition to the continued commercialization of Zasciato Clindamycin Phosphate Vaginal Gel 2%, the first FDA approved product to emerge from our portfolio, and a treatment for bacterial vaginosis in females aged 12 and older that became available nationwide by prescription earlier this year via our collaborator, Organon. We also discussed anticipated milestones focused on our first in category product candidates related to continuing to progress toward a phase three trial of Sidenafil cream 3.6%, which has the potential to be the first FDA approved treatment for female sexual arousal disorder. for which there are no FDA-approved treatments, and continuing to enroll in our phase three study of oviprene, are potentially first in category hormone-free monthly intravaginal contraceptive candidates. Today, we'll review our progress against the anticipated milestones for oviprene and sildenafil cream with a focus on providing context and metrics that are important to understanding the potential impact of these programs. We'll also highlight today the status of and what comes next for our two product candidates in the menopause space, our monthly vaginal hormone therapy for hot flashes and our hormone-free vaginal insert for sexual pain. Before I do, I'm going to first turn the call back over to our Chief Accounting Officer, Marty, to review our second quarter financial results.

Thanks, Sabrina, and thanks, everyone, for joining us today. I would now like to summarize DARI's financial results for the quarter ended June 30th, 2024, which I will refer to as the second quarter. As Sabrina mentioned, DARI's business strategy is to assemble and advance a portfolio of differentiated product candidates that address meaningful unmet needs we've identified in women's health, and then to monetize the value of our portfolio's clinical and regulatory advances over the near and long term. The investment required to build and advance a portfolio includes corporate overhead, portfolio acquisition and maintenance costs, and ongoing research and development, or R&D, expenses. During the second quarter of 2024, our general and administrative expenses, or G&A, were approximately $2.4 million, which is a 16% decrease compared to Q2 2023 due primarily to reduced headcount and reduced professional services expense. Our R&D expenses, which vary from period to period based on clinical, preclinical, manufacturing, regulatory, and other activities across our entire portfolio, were approximately $4.9 million for the second quarter, which is a 19% decrease compared to Q2 2023. As we guided previously this year, we continue to anticipate our full year 2024 R&D expenses will be less than our 2023 R&D expenses. Our comprehensive income for the second quarter was approximately $12.9 million, driven by proceeds from the royalty monetization transaction we closed in April. We ended the second quarter with approximately $16.4 million in cash and cash equivalents and had approximately 8.5 million shares of common stock outstanding as of August 9th, which reflects the reverse stock split that was implemented on July 1st, 2024. In April, we announced and closed a royalty monetization transaction with ZOMA, in which DARE received $22 million in gross proceeds, and following a pre-specified total return to ZOMA, ZOMA will make upside-sharing milestone payments to DARE equal to 50% of all remaining cash flows sold to ZOMA under the transaction. This monetization of future net royalty and net milestone payments accelerates potential cash flows from the future commercial success of Zosciato and ensures that DARE and our shareholders have the opportunity to participate meaningfully in Zasciato economics as commercialization progresses. This non-dilutive financing provides DARE with significant capital to help achieve our objectives and importantly allows us to focus on advancing our late-stage potential first-in-category investigational products, Ovacreen and Sildenafil creams, both of which represent large market opportunities. The structure of this transaction also underscores the significant potential of oviprene and sildenafilcrine, with DARA retaining the significant majority of future economics and the ability to achieve attractive margins through retained net sales in all commercial milestones. In the second quarter, we also received $1 million at the latest installment under our grant agreement with the Foundation in support of our investigational contraceptive, DARE-LARC-1. Under the terms of the grant agreement, DARE may receive a total of up to approximately $49 million to support non-clinical development of DARE-LARC-1. This funding will allow us to advance the development of DARE-LARC-1 through non-clinical proof-of-principle studies and other work to prepare for the submission of an investigational new drug application with the FDA, approval of which is required to begin testing in humans. To date, DARE has received approximately $29.3 million under the DARE-LARC-1 grant agreement. Together, the royalty financing and latest installment in grant funding represent our commitment to being creative, collaborative, and opportunistic in seeking capital needed to meet our objectives and to build shareholder value. We encourage investors to review the more detailed discussion of our financials, our financial condition, liquidity, capital resources, and risk factors in our Form 10-Q for the quarter ended June 30, 2024, which we filed this afternoon, as well as our annual Form 10-K, for the year ended December 31st, 2023, which was filed on March 28th, 2024. I'd now like to return the call back over to Sabrina.

Great. Thank you, Marty. I'm now going to talk through our 2024 accomplishments to date and some anticipated milestones with a focus on our late stage candidates to benefit cream and oviprene. But first, I'll provide an update on our on-market asset, Zosciato. So as a reminder, Zosciato, or clindamycin phosphate 2% vaginal gel, is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. It's a colorless, single-dose vaginal gel that can be applied at any time of day, and it's formulated with the goal of limiting leakage and increasing vaginal retention time, known as time spent in place. In the first quarter of 2024, through our commercialization agreement with Organon, Zasciato became available by prescription across the United States. The Organon women's health sales team continues to see steady month-over-month increases in total prescriptions of Zasciato and new prescriber volumes in line with the opportunity for a new branded entrant in the category. There are positive signals related to strong clinical acceptance among early adopters with multiple uses among trialists paired with a positive patient reception. And the team continues to unlock access channels for a frictionless fulfillment experience for both patients and providers. I'd now like to provide an update on Sidenafil Cream 3.6%. During the second quarter, we continued our interactions with the FDA on the development program for sodenafil cream as a treatment for female sexual arousal disorder, including with respect to the proposed efficacy endpoints to take forward into Phase III development. The patient population and the endpoints we proposed to the FDA for Phase III clinical development Those were our post-hoc analyses for the Phase 2B study data showed that Sidenafil cream demonstrated statistically significant and meaningful patient improvements. During the second quarter, we provided responsive materials to queries from the FDA regarding patient-reported outcomes and the qualitative assessments of within-patient clinically meaningful improvements that we saw in the Phase 2B study based on the participant exit interviews. While the FDA had indicated it anticipated providing additional feedback during the second quarter on the phase three design, which would be the first ever phase three pivotal study of a therapeutic candidate for the treatment of arousal disorder in women, its review is ongoing. And we look forward to providing updates on the FDA's feedback, the phase three study design and plans, as well as any relevant updates on our collaboration strategy as they become available. In preparation for Phase III initiation, during the second quarter, we completed the bid defense meetings with the CROs being considered for the Phase III studies and launched the manufacturing campaign to support Phase III. In terms of market and revenue potential, there are currently no FDA-approved treatments for any form of sexual arousal disorder in women, meaning Savenafil cream has the potential to be the first. Sidenafil is the active ingredient in tablet form for oral administration, currently marketed under the brand name Viagra for the treatment of erectile dysfunction in men, which was undoubtedly one of the most successful prescription products ever launched. And market research suggests that approximately 20 million women in the U.S. experience symptoms of low or no sexual arousal. In terms of probability of success, we've already demonstrated that sidenafil cream increased genital blood tissue flow in quantitative studies. And as we previously shared, we've completed all of the study analyses and data from the exploratory face-to-be-respond clinical trial of sidenafil cream and identified the patient population that received the greatest benefit from sidenafil cream in their genital arousal response. The efficacy findings and details regarding this patient population were published in the Journal of Obstetrics and Gynecology, which is the official journal of the American College of Obstetrics and Gynecology, or ACOG, and were available open access online in June. And our publication was featured, as the featured article, in July for In the Green Room, which is the ACOG podcast. Our study was also spotlighted in an editorial in the journal. It's a distinct honor to be featured, and we are pleased to see the medical community so engaged in these first-of-its-kind data around such a significant unmet need. We look forward to providing additional updates on the development program as they are available. In terms of oviprene, we also want to provide an update on the advancement of the phase three study of oviprene, which is our novel investigational hormone-free monthly intravaginal contraceptive, whose U.S. commercial rights are under a license agreement with Bayer. Non-hormonal contraception represents a significant commercial market opportunity, as there are currently no monthly hormone-free contraceptives approved by the FDA. Obaprene has potential to be a disruptive product in the contraceptive category and an important option for women who cannot use hormone-based birth control products or prefer not to do so. Based on market research, approximately 35 million women in the U.S. are potential candidates for Obaprene. Working with study collaborators at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, of the National Institutes of Health, or NIH, we commenced patient enrollment in the Evergreen Pivotal Phase III clinical study in December of 2023. Recruitment is currently underway at 20 sites across the United States, and it's supported by a central advertising campaign for the study that launched in March of this year, March 2024. You can see the campaign materials by visiting our website homepage. While there are 20 sites currently recruiting, it's clear that a subset of approximately half of those sites are the most successful in translating into study participants the considerable interest we have seen from women in response to the central advertising campaign. As a result, we have a range of enrollment projections that vary considerably based on the enrollment rates at our most successful sites versus those that are not enrolling at a similar pace. As a reminder, this study aims to enroll sufficient participants across the study sites to have approximately 250 participants complete approximately 12 months, which is 13 menstrual cycles, of product use. Based on the current average enrollment rate across all of the 20 sites, we anticipate that approximately 125 women, which is half of our target number of participants to complete the study, will complete approximately six months of product use by the end of the second quarter in 2025. We are of course looking at strategies to ensure that all of the study sites are equally successful and productive and look forward to providing updates on enrollment projections and rates as enrollment progresses in the coming quarters. Based on communications to date with the FDA, if successful, we believe that just this single registration study will be required to support a premarket approval application submission with the FDA. I'd now like to turn to DARE HRT-1 and DARE VBA-1. Because lastly, given the unveiling earlier this year of a bipartisan Senate bill that would authorize $275 million to boost research, training, and public awareness around menopause and midlife women's health issues, an area that has often been too stigmatized, overlooked, and underfunded, we've been getting lots of questions about our menopause-related programs. DARE-HRT1 is a potential first vaginal monthly therapy for the vasomotor symptoms of menopause. This is a program we are preparing for the single phase 3 clinical study we believe will be required for approval via the FDA's 505B2 pathway. In addition, DARE-VVA1, which is our hormone-free vaginal candidate for sexual pain due to the vulvar and vaginal atrophy, or VVA, associated with menopause, is phase 2 ready. and we're actively exploring opportunities to move this program forward. We're looking forward to seeing continued progress in the menopause space and potential progress of this new bill, and we'll provide updates on our DARE HRT-1 and DARE VDA-1 programs as available. In summary, we continue to progress our portfolio of potential first and category product candidates and look forward to providing more updates this year as we work to advance some of the most potentially disruptive candidates for the health and well-being of women in decades, collaborating with leading companies, including Organon for Zosciato and Bayer for Oviprene, to commercialize and deliver these treatments to as many women as possible. I'd now like to turn the call over to the operator for Q&A.

Thank you. We will now begin the question and answer session. At this time, I would like to remind everyone in order to ask a question, press the star and then the number one on your telephone keypad. If you are called upon to ask your question and are listening by a loudspeaker on your device, please pick up your handset and ensure that your phone is not on mute when asking your question. We will pause for a moment to compile the question and answer roster. Your first question comes from the line of Catherine Novak of Jones Research. Please go ahead.

Hi. Good afternoon. Congrats on all the progress this quarter. I wanted to ask again for overprinting. With the timing updates that you gave today, can you give us a sense of what implication this has for top line readout? And then given that this is single arm, do you have any plans for an interim look? so we can see data a little bit sooner?

Yeah, absolutely. Those are great questions. We don't have timing yet for top line. You know, as I mentioned in the prepared remarks, there's a difference in enrollment rate between some of the sites. And I want to be clear, there's not a difference in demand. So the central advertising campaign has been quite successful in terms of generating patient interest in the study. quite equitably across the sites. It's just a difference in terms of how successful some of the sites are translating those women into study participants from that considerable interest. And so we felt comfortable at this time projecting when we'll have, right, half of the subjects having completed about halfway through, right, six months of their assessments. We definitely look forward to giving more updates, including an opportunity to do an interim analysis at that point, but we're not prepared yet to give exact timing on final top line. We really want to get a little further in enrollment and a little further in, you know, looking at some of these strategies we've been implementing to help all the sites be equally successful and productive in pulling those patients that have expressed interest forward.

Great.

And then, again, since this is single-armed, Can you remind us the typical use of PERL index that would make this commercially compelling asset?

Yeah, it's a great question. So the non-hormonal category for – so first of all, I should take a step back. So PERL index is how contraceptive methods are evaluated by the FDA, and it's the metrics that's used regardless of whether it's a hormonal product or a non-hormonal product. And FDA-approved products have a very wide range of PERL indices. So most effective is one that's like an intrauterine device, right, which is implanted. And the least effective of the FDA-approved methods are the spermicides, the vaginal gels, which have a PERL index in the 27 to 28 range. So it's a very broad range. And in the non-hormonal category, there really are not that many options. And the options that are available, other than the copper IUD, which is in that one range, the other options are at the other end of the spectrum, closer to the 27 to 28 or are the 27 to 28 range. So as we think about a product like oviprene, it would be the first product to be a once a month. So all the other non-hormonal products other than the copper IUD are pericoidal, meaning they're used in the method, think condoms, think spermicide. So it would be different in that regard. And based on the pre-pivotal study data that's been generated, that study suggests that the surrogate marker that's used for that study in contraceptive effectiveness, that it has the potential to be in the same range as the hormonal methods, the short-acting hormonal methods like pills, patches, rings. But the bar is fairly low, right, for the non-hormonal methods given what some of the other approved products are. And that really means from an acceptability perspective, there's really a wide range of efficacy that could be very acceptable for a method like oviprene given that it also has convenience. that none of the other non-hormonal methods have. So the pre-pivotal data suggests that it has that opportunity for effectiveness in the same range as the short-acting or hormonal methods. And then to your question, Catherine, the range in general, though, for non-hormonal methods is actually quite wide, which really speaks to, in the end, you know, it's all about Contraceptive methods that women will use, and that's why the FDA has approved such a wide range of contraceptive effectiveness. So there's a wide range, therefore, of acceptability and commercial viability for products like oviprene, particularly given that it would be the only once-a-month method that's available, right, non-pericoidal method or non-implanted method that would be available in the hormone-free category.

Great. That's helpful. Looking forward to getting more updates from the program down the line.

Absolutely. Thank you. Thank you.

Again, if you would like to ask a question, press the star and then the number one on your telephone keypad. Your next question comes from the line of Douglas Chow of HC, Wainwright & Co. Please go ahead.

Hi, good afternoon. Thanks for taking the questions. I guess, Sabrina, in terms of your interactions with the FDA for this Adrenal Cell Screening Program, I guess, I'm just curious, are you anticipating another meeting being needed to sort of get this final alignment, or do you think your sort of interactions are sufficient to to get this settled?

Yeah, Doug, that's a great question. You know, it's definitely clear that, which we know, right, this is a first in category indication and a first in category product. And there's a lot of data for the FDA to go through. And there's also a lot of kind of key opinion leader support that we have provided to the FDA historically, right, in terms of understanding of the indication, understanding of the outcome measures. So there may be questions or circumstances where that's helpful. Not clear at this time. Right now, the questions have really been straightforward in terms of, you know, kind of the typical things. We're providing a lot of, as I said, information around those outcome measures and what's a clinically meaningful improvement, and there's a whole very specialized assessment in the patient-reported outcome world called the psychometric analysis and assessment that was done. So a lot of the information we're providing is really providing that color. But to be determined, you know, we'll definitely be open to that. We, to date, have had a number of meetings with the FDA, and when we've had them in the past, they've definitely been super productive, so we're definitely open to that. But at this point, you know, nothing definitive in that front.

Okay. And just, you know, you obviously have a very rich pipeline with a lot of opportunities. I guess How are you thinking about sort of prioritizing things in the context of your balance sheet and, you know, what you can afford to do right now?

Yeah, another great question. So as we've, you know, really been trying to highlight oviprene and sidenafil as our two, you know, either in phase three as oviprene is or getting phase three ready as sidenafil is, those have really been our priorities, both operationally you know, in terms of where we put our bandwidth, but also obviously financially as well. And those, you know, those really remain the priority. However, to your point, we have a very deep pipeline, and particularly with a lot of the noise around menopause lately, we've been getting a lot of questions and interest broadly around our menopause programs that we have, the two that I highlighted today. So we're also, you know, doing everything we can to make sure that we are advancing those programs as much as possible operationally by being very capital responsible and really focusing our priorities around Obaprene and Sudenafil right now responsibly with our capital.

Okay, great. Thank you so much.

Absolutely.

That concludes our question and answer session. I would like to turn the call back over to Sabrina Matusi-Johnson for any additional or closing remarks.

Great. Well, thank you all for taking the time this afternoon to hear about our recent updates and our ongoing commitment to drive value for all of our DARI stakeholders by identifying and advancing potential new therapies to provide additional choices, enhanced outcomes, and ease of use for women. As you heard today, we continue to make great progress and are excited for what the rest of this year holds for DARE. As we look ahead to the rest of 2024, we expect several milestones this year, including more of a pre and pivotal study updates, as I indicated, as we work to complete what we expect to be that single registration study, and as we've just been talking about, updates on our discussions with the FDA. and the activities that we're doing to commence that phase three for our potential first in category treatment option for women with sexual arousal disorder to then it's all cream. And as we also touched on on the end, at the end of the call, our unique model really also has a deep pipeline and support of commercial collaborators and therefore we believe we're well positioned to accelerate innovation for women everywhere while also driving value for all of DARI stakeholders. We look forward to keeping you updated on our progress towards the milestones we discussed today. Thank you. Thank you. Thank you. Thank you. Thank you. I'm you Bye. you

Welcome to the conference call hosted by DARE Bioscience to review the company's second quarter financial results and to provide a general business update. This call has been recorded. My name is Leonardo, and I will be your operator today. With us today from DARE are Sabina Martusi-Johnson, President and Chief Executive Officer, and Marty Herring-Layton, Chief Accounting Officer. Ms. Herring-Layton, please proceed.

Good afternoon and welcome to the DARA Bioscience Financial Results and Business Update call for the quarter ended June 30th, 2024. Today we will review our second quarter results and discuss developments and expectations for our pipeline and portfolio. I'd like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filing including on form 10Q for the quarter ended June 30th, 2024, which was filed today. I would also like to point out that the content of this call includes time sensitive information that is current as of today, August 12th, 2024. SARA undertakes no obligation to update any forward looking statements to reflect new information or developments after this call, except as required by law. I will now turn it over to Sabrina.

Thank you. I always like to start our quarterly calls by taking a minute to remind those of you who may be newer to the DARE story of our purpose and our mission. We believe DARE is the only publicly traded company focused solely on women's health, pharmaceutical product development broadly, and we remain dedicated to advancing disruptive products for the health and well-being of women through clinical development, regulatory review, and ultimately to market. Our commitment and focus is to improve health outcomes and the lives of women by leveraging the basic science and pharmacology that is understood about certain active pharmaceutical ingredients and marketed products to accelerate innovative treatments that women want and need by boldly addressing existing therapeutic gaps. We seek to optimize these treatments for our target indications to enhance outcomes, convenience, and side effect profile. or to address a novel indication where the pharmacology is well-suited but has not previously been applied to the indication in question for women. We believe we have the broadest portfolio of potential high-impact, first-in-category product candidates to improve the health and well-being of women, many of which have already demonstrated proof of concept, and that our robust pipeline positions us well for the short, medium, and long term. During our last update call, we discussed the strides we made last year to advance innovative therapies for women and the key milestones anticipated for 2024. In addition to the continued commercialization of Zasciato Clindamycin Phosphate Vaginal Gel 2%, the first FDA-approved product to emerge from our portfolio, and a treatment for bacterial vaginosis in females age 12 and older that became available nationwide by prescription earlier this year, via our collaborator, Organon. We also discussed anticipated milestones focused on our first-in-category product candidates related to continuing to progress toward a Phase III trial of Sidenafil Cream 3.6%, which has the potential to be the first FDA-approved treatment for female sexual arousal disorder, for which there are no FDA-approved treatments, and continuing to enroll in our Phase III study of Oviprene, are potentially first in category hormone-free monthly intravaginal contraceptive candidates. Today, we'll review our progress against the anticipated milestones for oviprene and subenafil cream with a focus on providing context and metrics that are important to understanding the potential impact of these programs. We'll also highlight today the status of and what comes next for our two product candidates in the menopause space, our monthly vaginal hormone therapy for hot flashes, and our hormone-free vaginal insert for sexual pain. Before I do, I'm going to first turn the call back over to our Chief Accounting Officer, Marty, to review our second quarter financial results.

Thanks, Sabrina, and thanks, everyone, for joining us today. I would now like to summarize DARI's financial results for the quarter ended June 30, 2024, which I will refer to as the second quarter. As Sabrina mentioned, DARI's business strategy is to assemble and advance a portfolio of differentiated product candidates that address meaningful unmet needs we've identified in women's health, and then to monetize the value of our portfolio's clinical and regulatory advances over the near and long term. The investment required to build and advance a portfolio includes corporate overhead, portfolio acquisition and maintenance costs, and ongoing research and development or R&D expenses. During the second quarter of 2024, our general and administrative expenses, or G&A, were approximately $2.4 million, which is a 16% decrease compared to Q2 2023 due primarily to reduced headcount and reduced professional services expense. Our R&D expenses, which vary from period to period based on clinical, preclinical, manufacturing, regulatory, and other activities across our entire portfolio, were approximately 4.9 million for the second quarter, which is a 19% decrease compared to Q2 2023. As we guided previously this year, we continue to anticipate our full year 2024 R&D expenses will be less than our 2023 R&D expenses. Our comprehensive income for the second quarter was approximately 12.9 million, driven by proceeds from the royalty monetization transaction we closed in April. We ended the second quarter with approximately $16.4 million in cash and cash equivalents and had approximately 8.5 million shares of common stock outstanding as of August 9th, which reflects the reverse stock split that was implemented on July 1st, 2024. In April, we announced and closed a royalty monetization transaction with ZOMA in which DARE received $22 million in gross proceeds and following a pre-specified total return to ZOMA, Zoma will make upside-sharing milestone payments to DARE equal to 50% of all remaining cash flows sold to Zoma under the transaction. This monetization of future net royalty and net milestone payments accelerates potential cash flows from the future commercial success of Zosciato and ensures that DARE and our shareholders have the opportunity to participate meaningfully in Zosciato economics as commercialization progresses. This non-dilutive financing provides DARA with significant capital to help achieve our objectives and importantly allows us to focus on advancing our late-stage potential first-in-category investigational products, ovoprene and sildenafilcrene, both of which represent large market opportunities. The structure of this transaction also underscores the significant potential of ovoprene and sildenafilcrene, with DARA retaining the significant majority of future economics and the ability to achieve attractive margins through retained net sales in all commercial milestones. In the second quarter, we also received $1 million as the latest installment under our grant agreement with the Foundation in support of our investigational contraceptive, DER-LARC-1. Under the terms of the grant agreement, DARA may receive a total of up to approximately $49 million to support non-clinical development of DER-LARC-1. This funding will allow us to advance the development of DARE-LARC-1 through non-clinical proof-of-principle studies and other work to prepare for the submission of an investigational new drug application with the FDA, approval of which is required to begin testing in humans. To date, DARE has received approximately $29.3 million under the DARE-LARC-1 grant agreement. Together, the royalty financing and latest installment in grant funding represent our commitment to being creative, collaborative, and opportunistic in seeking capital needed to meet our objectives and to build shareholder value. We encourage investors to review the more detailed discussion of our financials, our financial condition, liquidity, capital resources, and risk factors in our Form 10-Q for the quarter ended June 30, 2024, which we filed this afternoon, as well as our annual Form 10-K for the year ended December 31, 2023, which was filed on March 28, 2024. I'd now like to return the call back over to Sabrina.

Great. Thank you, Marty. I'm now going to talk through our 2024 accomplishments to date and some anticipated milestones with a focus on our late-stage candidates to benefit cream and oviprene. But first, I'll provide an update on our on-market asset, Zosciato. So as a reminder, Zosciato, or clindamycin phosphate 2% vaginal gel, is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. It's a colorless, single-dose vaginal gel that can be applied at any time of day, and it's formulated with the goal of limiting leakage and increasing vaginal retention time, known as time spent in place. In the first quarter of 2024, through our commercialization agreement with Organon, Zasciato became available by prescription across the United States. The Organon women's health sales team continues to see steady month-over-month increases in total prescriptions of Zasciato and new prescriber volumes in line with the opportunity for a new branded entrant in the category. There are positive signals related to strong clinical acceptance among early adopters with multiple uses among trialists paired with a positive patient reception. And the team continues to unlock access channels for a frictionless fulfillment experience for both patients and providers. I'd now like to provide an update on Sidenafil Cream 3.6%. During the second quarter, we continued our interactions with the FDA on the development program for sodenafil cream as a treatment for female sexual arousal disorder, including with respect to the proposed efficacy endpoints to take forward into Phase III development. The patient population and the endpoints we proposed to the FDA for Phase III clinical development Those were our post-hoc analyses for the Phase 2B study data showed that Sidenafil cream demonstrated statistically significant and meaningful patient improvements. During the second quarter, we provided responsive materials to queries from the FDA regarding patient-reported outcomes and the qualitative assessments of within-patient clinically meaningful improvements that we saw in the Phase 2B study based on the participant exit interviews. While the FDA had indicated it anticipated providing additional feedback during the second quarter on the phase three design, which would be the first ever phase three pivotal study of a therapeutic candidate for the treatment of arousal disorder in women, its review is ongoing. And we look forward to providing updates on the FDA's feedback, the phase three study design and plans, as well as any relevant updates on our collaboration strategy as they become available. In preparation for Phase III initiation, during the second quarter, we completed the bid defense meetings with the CROs being considered for the Phase III studies and launched the manufacturing campaign to support Phase III. In terms of market and revenue potential, there are currently no FDA-approved treatments for any form of sexual arousal disorder in women, meaning Savenafil cream has the potential to be the first. Sudenafil is the active ingredient in tablet form for oral administration, currently marketed under the brand name Viagra, for the treatment of erectile dysfunction in men, which was undoubtedly one of the most successful prescription products ever launched. And market research suggests that approximately 20 million women in the U.S. experience symptoms of low or no sexual arousal. In terms of probability of success, we've already demonstrated that sidenafil cream increased genital blood tissue flow in quantitative studies. And as we previously shared, we've completed all of the study analyses and data from the exploratory face-to-be-respond clinical trial of sidenafil cream and identified the patient population that received the greatest benefit from sidenafil cream in their genital arousal response. The efficacy findings and details regarding this patient population were published in the Journal of Obstetrics and Gynecology, which is the official journal of the American College of Obstetrics and Gynecology, or ACOG, and were available open access online in June. And our publication was featured, as the featured article, in July for In the Green Room, which is the ACOG podcast. Our study was also spotlighted in an editorial in the journal. It's a distinct honor to be featured, and we are pleased to see the medical community so engaged in these first-of-its-kind data around such a significant unmet need. We look forward to providing additional updates on the development program as they are available. In terms of oviprene, we also want to provide an update on the advancement of the phase three study of oviprene, which is our novel investigational hormone-free monthly intravaginal contraceptive, whose U.S. commercial rights are under a license agreement with Bayer. Non-hormonal contraception represents a significant commercial market opportunity, as there are currently no monthly hormone-free contraceptives approved by the FDA. Obaprene has potential to be a disruptive product in the contraceptive category and an important option for women who cannot use hormone-based birth control products or prefer not to do so. Based on market research, approximately 35 million women in the U.S. are potential candidates for Obaprene. Working with study collaborators at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, of the National Institutes of Health, or NIH, we commenced patient enrollment in the Evergreen Pivotal Phase III clinical study in December of 2023. Recruitment is currently underway at 20 sites across the United States, and it's supported by a central advertising campaign for the study that launched in March of this year, March 2024. You can see the campaign materials by visiting our website homepage. While there are 20 sites currently recruiting, it's clear that a subset of approximately half of those sites are the most successful in translating into study participants that considerable interest we have seen from women in response to the central advertising campaign. As a result, we have a range of enrollment projections that vary considerably based on the enrollment rates at our most successful sites versus those that are not enrolling at a similar pace. As a reminder, this study aims to enroll sufficient participants across the study sites to have approximately 250 participants complete approximately 12 months, which is 13 menstrual cycles, of product use. Based on the current average enrollment rate across all of the 20 sites, We anticipate that approximately 125 women, which is half of our target number of participants to complete the study, will complete approximately six months of product use by the end of the second quarter in 2025. We are, of course, looking at strategies to ensure that all of the study sites are equally successful and productive and look forward to providing updates on enrollment projections and rates as enrollment progresses in the coming quarters. Based on communications to date with the FDA, if successful, we believe that just this single registration study will be required to support a premarket approval application submission with the FDA. I'd now like to turn to DARE HRT-1 and DARE VBA-1. Because lastly, given the unveiling earlier this year of a bipartisan Senate bill that would authorize $275 million to boost research, training, and public awareness around menopause and midlife women's health issues, an area that has often been too stigmatized, overlooked, and underfunded, we've been getting lots of questions about our menopause-related programs. DARE HRT1 is a potential first vaginal monthly therapy for the vasomotor symptoms of menopause. This is a program we are preparing for the single phase three clinical study we believe will be required for approval via the FDA's 505B2 pathway. In addition, DARE VVA1, which is our hormone-free vaginal candidate for sexual pain due to the vulvar and vaginal atrophy, or VVA, associated with menopause, is phase two ready. and we're actively exploring opportunities to move this program forward. We're looking forward to seeing continued progress in the menopause space and potential progress of this new bill, and we'll provide updates on our DARE HRT1 and DARE VDA1 programs as available. In summary, we continue to progress our portfolio of potential first-in-category product candidates and look forward to providing more updates this year as we work to advance some of the most potentially disruptive candidates for the health and well-being of women in decades, collaborating with leading companies, including Organon for Zosciato and Bayer for Obaprene, to commercialize and deliver these treatments to as many women as possible. I'd now like to turn the call over to the operator for Q&A.

Thank you. We will now begin the question and answer session. At this time, I would like to remind everyone in order to ask a question, press the star and then the number one on your telephone keypad. If you are called upon to ask your question and are listening by a loudspeaker on your device, please pick up your handset and ensure that your phone is not on mute when asking your question. We will pause for a moment to compile the question and answer roster. Your first question comes from the line of Catherine Novak of Jones Research. Please go ahead.

Hi. Good afternoon. Congrats on all the progress this quarter. I wanted to ask again for overprinting. With the timing updates that you gave today, can you give us a sense of what implication this has for top line readout? And then given that this is single arm, do you have any plans for an interim look? so we can see data a little bit sooner?

Yeah, absolutely. Those are great questions. We don't have timing yet for top line. You know, as I mentioned in the prepared remarks, there's a difference in enrollment rate between some of the sites. And I want to be clear, there's not a difference in demand. So the central advertising campaign has been quite successful in terms of generating patient interest in the study. quite equitably across the sites. It's just a difference in terms of how successful some of the sites are translating those women into study participants from that considerable interest. And so we felt comfortable at this time projecting when we'll have, right, half of the subjects having completed about halfway through, right, six months of their assessments. We definitely look forward to giving more updates, including an opportunity to do an interim analysis at that point, but we're not prepared yet to give exact timing on final top line. We really want to get a little further in enrollment and a little further in, you know, looking at some of these strategies we've been implementing to help all the sites be equally successful and productive in pulling those patients that have expressed interest forward.

Great.

And then, again, since this is single-armed, Can you remind us the typical use PERL index that would make this commercially compelling asset?

Yeah, it's a great question. So the non-hormonal category for, so first of all, I should take a step back. So PERL index is how contraceptive methods are evaluated by the FDA, and it's the metrics that's used regardless of whether it's a hormonal product or a non-hormonal product. FDA-approved products have a very wide range of PERL indices. So most effective is one that's like an intrauterine device, right, which is implanted. And the least effective of the FDA-approved methods are the spermicides, the vaginal gels, which have a PERL index in the 27 to 28 range. So it's a very broad range. And in the non-hormonal category, there really are not that many options. And the options that are available, other than the copper IUD, which is in that one range, the other options are at the other end of the spectrum, closer to the 27 to 28 or are the 27 to 28 range. So as we think about a product like oviprene, it would be the first product to be a once a month. So all the other non-hormonal products other than the copper IUD are pericoidal, meaning they're used in the method, think condoms, think spermicide. So it would be different in that regard. And based on the pre-pivotal study data that's been generated, that study suggests that the surrogate marker that's used for that study in contraceptive effectiveness, that it has the potential to be in the same range as the hormonal methods, the short-acting hormonal methods like pills, patches, rings. But the bar is fairly low, right, for the non-hormonal methods given what some of the other approved products are. And that really means from an acceptability perspective, there's really a wide range of efficacy that could be very acceptable for a method like oviprene given that it also has convenience. that none of the other non-hormonal methods have. So the pre-pivotal data suggests that it has that opportunity for effectiveness in the same range as the short-acting or hormonal methods. And then to your question, Catherine, the range in general, though, for non-hormonal methods is actually quite wide, which really speaks to, in the end, you know, it's all about Contraceptive methods that women will use, and that's why the FDA has approved such a wide range of contraceptive effectiveness. So there's a wide range, therefore, of acceptability and commercial viability for products like oviprene, particularly given that it would be the only once-a-month method that's available, right, non-pericoidal method or non-implanted method that would be available in the hormone-free category.

Great. That's helpful. Looking forward to getting more updates from the program down the line.

Absolutely. Thank you.

Again, if you would like to ask a question, press the star and then the number one on your telephone keypad. Your next question comes from the line of Douglas Chow of HC, Wainwright & Co. Please go ahead.

Hi, good afternoon. Thanks for taking the questions. I guess, Sabrina, in terms of your interactions with the FDA for the Sedano-Phil screening program, I guess I'm just curious, are you anticipating another meeting being needed to sort of get this final alignment, or do you think your sort of interactions are sufficient? to get this settled?

Yeah, Doug, that's a great question. You know, it's definitely clear that, which we know, right, this is a first in category indication and a first in category product. And there's a lot of data for the FDA to go through. And there's also a lot of information kind of key opinion leader support that we have provided to the FDA historically, right, in terms of understanding of the indication, understanding of the outcome measures. So, there may be questions or circumstances where that's helpful. Not clear at this time. Right now, the questions have really been straightforward in terms of, you know, kind of the typical things. We're providing a lot of, as I said, information around those outcome measures and what's a clinically meaningful improvement, and there's a whole very specialized assessment in the patient-reported outcome world called the psychometric analysis and assessment that was done. So a lot of the information we're providing is really providing that color. But to be determined, you know, we'll definitely be open to that. We, to date, have had a number of meetings with the FDA, and when we've had them in the past, they've definitely been super productive, so we're definitely open to that. But at this point, you know, nothing definitive in that front.

Okay. And just, you know, you obviously have a very rich pipeline with a lot of opportunities. I guess How are you thinking about sort of prioritizing things in the context of your balance sheet and, you know, what you can afford to do right now?

Yeah, another great question. So as we've, you know, really been trying to highlight oviprene and sidenafil as our two, you know, either in phase three as oviprene is or getting phase three ready as sidenafil is, those have really been our priorities, both operationally and you know, in terms of where we put our bandwidth, but also obviously financially as well. And those, you know, those really remain the priority. However, to your point, we have a very deep pipeline, and particularly with a lot of the noise around menopause lately, we've been getting a lot of questions and interest broadly around our menopause programs that we have, the two that I highlighted today. So we're also, you know, doing everything we can to make sure that we are advancing those programs as much as possible operationally by being very capital responsible and really focusing our priorities around oviprene and sidenafil right now responsibly with our capital.

Okay, great. Thank you so much.

Absolutely.

That concludes our question and answer session. I would like to turn the call back over to Sabrina Matusi-Johnson for any additional or closing remarks.

Great. Well, thank you all for taking the time this afternoon to hear about our recent updates and our ongoing commitment to drive value for all of our DARI stakeholders by identifying and advancing potential new therapies to provide additional choices, enhanced outcomes, and ease of use for women. As you heard today, we continue to make great progress and are excited for what the rest of this year holds for DARE. As we look ahead to the rest of 2024, we expect several milestones this year including More of a pre and pivotal study updates, as I indicated, as we work to complete what we expect to be that single registration study. And as we've just been talking about, updates on our discussions with the FDA and the activities that we're doing to commence that phase three for our potential first in category treatment option for women with sexual arousal disorder to then fill cream. And as we also touched on on the end, at the end of the call, our unique model really also has deep pipeline and support of commercial collaborators, and therefore we believe we're well positioned to accelerate innovation for women everywhere, while also driving value for all of DARI's stakeholders. We look forward to keeping you updated on our progress towards the milestones we discussed today. Thank you.

Is that today's call? Thank you all for joining. You may now disconnect.